Schott Pharma AG KGaAFRA:1SX +0.50%67 Piotroski F-Score is 7 as of Jun. 30, 2026, which is 17% above its 10-year median of 6.00. GuruFocus rates FRA:1SX with a GF Score™ of 67/100 and a GF Value™ of €6.49. The stock has 2 warning signs investors should review. Among 806 Medical Devices & Instruments companies, Schott Pharma AG KGaA ranks better than 92.56% on this metric.
Good Sign:
Piotroski F-Score is 7, indicates a very healthy situation.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Schott Pharma AG KGaA has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.
The historical rank and industry rank for Schott Pharma AG KGaA's Piotroski F-Score or its related term are showing as below:
FRA:1SX'
s Piotroski F-Score Range Over the Past 10 Years
Min: 5 Med: 6 Max: 7
Current: 7
During the past 6 years, the highest Piotroski F-Score of Schott Pharma AG KGaA was 7. The lowest was 5. And the median was 6.
Schott Pharma AG KGaA (FRA:1SX) Piotroski F-Score Explanation
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Schott Pharma AG KGaA Piotroski F-Score Related Terms
Schott Pharma AG KGaA Piotroski F-Score Historical Data
* Premium members only.
The historical data trend for Schott Pharma AG KGaA's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:1SX vs ISRG, BDX, MDLN: Piotroski F-Score Comparison
For the Medical Instruments & Supplies subindustry, Schott Pharma AG KGaA's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Schott Pharma AG KGaA Piotroski F-Score vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Schott Pharma AG KGaA's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Schott Pharma AG KGaA's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Schott Pharma AG KGaA's current Net Income (TTM) was 143.3.
==> Positive ==> Score 1.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Schott Pharma AG KGaA's current Cash Flow from Operations (TTM) was 202.5.
==> Positive ==> Score 1.
Question 3. Change in Return on Assets
Compare this year's return on assets (1) to last year's return on assets.
Schott Pharma AG KGaA's return on assets of this year was 0.09645904. Schott Pharma AG KGaA's return on assets of last year was 0.10894685.
==> Last year is higher ==> Score 0.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Schott Pharma AG KGaA's gearing of this year was 0. Schott Pharma AG KGaA's gearing of last year was 0.05635584.
==> This year is lower or equal to last year. ==> Score 1.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Schott Pharma AG KGaA's current ratio of this year was 1.5869227. Schott Pharma AG KGaA's current ratio of last year was 1.42942542.
==> This year's current ratio is higher. ==> Score 1.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Schott Pharma AG KGaA's number of shares in issue this year was 590.724. Schott Pharma AG KGaA's number of shares in issue last year was 610.192.
==> There is smaller number of shares in issue this year, or the same. ==> Score 1.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Schott Pharma AG KGaA's gross margin of this year was 0.32962844. Schott Pharma AG KGaA's gross margin of last year was 0.3292886.
==> This year's gross margin is higher. ==> Score 1.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Schott Pharma AG KGaA's asset turnover of this year was 0.66776041. Schott Pharma AG KGaA's asset turnover of last year was 0.71645225.
==> Last year's asset turnover is higher ==> Score 0.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
1
+
1
+
0
+
1
+
1
+
1
+
1
+
1
+
0
=
7
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Schott Pharma AG KGaA has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.
Schott Pharma AG KGaA (FRA:1SX) has a Piotroski F-Score of 7 as of Jun. 30, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Schott Pharma AG KGaA and its competitors. This is 17% above median its historical median of 6.00. Over the past decade, Schott Pharma AG KGaA's Piotroski F-Score has ranged from 5.00 to 7.00. According to the industry distribution chart, Schott Pharma AG KGaA ranks #60 out of 806 companies in the Medical Devices & Instruments industry, placing it in the top 7.4%.
Is Schott Pharma AG KGaA's Piotroski F-Score too high?
Schott Pharma AG KGaA's current Piotroski F-Score of 7 is 17% above median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 5.00 to a high of 7.00. The Medical Devices & Instruments industry median Piotroski F-Score is 5.00. Schott Pharma AG KGaA's value of 7 is 40% above this industry median. Based on the distribution chart, Schott Pharma AG KGaA ranks #60 out of 806 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Schott Pharma AG KGaA has a GF Score™ of 67/100, reflecting its overall financial health beyond just this single metric.
How does Schott Pharma AG KGaA's Piotroski F-Score compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Schott Pharma AG KGaA ranks #60 out of 806 companies for Piotroski F-Score. This places Schott Pharma AG KGaA in the top 7% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. Schott Pharma AG KGaA's value of 7 is 40% above this benchmark. Historically, Schott Pharma AG KGaA's own Piotroski F-Score has ranged from 5.00 to 7.00 over the past decade. While the company's 10-year median is 6.00 vs. the industry median of 5.00, Schott Pharma AG KGaA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Medical Devices & Instruments company?
The median Piotroski F-Score among Medical Devices & Instruments companies is 5.00, based on 806 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Schott Pharma AG KGaA's current Piotroski F-Score of 7 is 40% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Schott Pharma AG KGaA and its competitors. For the Medical Devices & Instruments industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Schott Pharma AG KGaA's current Piotroski F-Score is 7, which is 17% above median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Schott Pharma AG KGaA stock overvalued right now?
Schott Pharma AG KGaA (FRA:1SX) has a current Piotroski F-Score of 7. The stock's GF Value™ is €6.49, compared to a current price of €4.06 — trading 37.4% below its estimated fair value. The current Piotroski F-Score is 7, which is 17% above median its 10-year median of 6.00 and 40% above the Medical Devices & Instruments industry median of 5.00. Schott Pharma AG KGaA's overall GF Score™ is 67/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Schott Pharma AG KGaA (FRA:1SX), the current Piotroski F-Score is 7 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Schott Pharma AG KGaA (FRA:1SX) Overvalued in 2026?
Based on GuruFocus' analysis, Schott Pharma AG KGaA stock appears to be undervalued.
The current stock price of €4.06 is trading 37.4% below its estimated GF Value™ of €6.49.
Key valuation signals for FRA:1SX:
Piotroski F-Score: 7 (17% above median its 10-year median of 6.00)
GF Value™: €6.49 vs. price of €4.06 (37.4% below fair value)
Industry Position: 40% above the Medical Devices & Instruments median (#60 of 806)
No single metric tells the full story. See the FRA:1SX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Schott Pharma AG & CO KGaA is an international provider of drug containment solutions and delivery systems for injectable drugs for pharma, biotech and life-sciences. Its business operates in two segments: Drug Containment Solutions (DCS) and Drug Delivery Systems (DDS). The majority of revenue is being generated from the DCS segment, which includes products like vials, cartridges, and ampoules, and provides customers with sterile and non-sterile options in standard and high-end formats for drug storage. Geographically, the company generates revenue from Europe, the Middle East, Africa (EMEA), Asia and the South Pacific, North America, and South America.
67GF Score
Get the complete analysis for FRA:1SX
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:1SX has been successfully added to your 
